Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.
Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.
The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for
After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on putting patients at the centre of the company and providing medical lead
A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
